Artivion (NYSE:AORT) Hits New 12-Month High – Still a Buy?

Artivion, Inc. (NYSE:AORT) shares reached a new 52-week high on Tuesday . The company traded as high as $30.11 and last traded at $30.11, with a volume of 87857 shares changing hands. The stock had previously closed at $29.00.

Analyst Ratings Changes

AORT has been the topic of a number of analyst reports. JMP Securities restated a “market outperform” rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday. Oppenheimer raised their price objective on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Stifel Nicolaus upped their target price on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $34.00 price target on shares of Artivion in a research note on Monday. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $31.80.

Artivion Trading Up 2.9 %

The company has a 50 day simple moving average of $27.43 and a 200 day simple moving average of $26.07. The company has a market capitalization of $1.25 billion, a PE ratio of -1,465.50 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Insider Buying and Selling

In related news, CAO Amy Horton sold 12,430 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now directly owns 139,989 shares in the company, valued at approximately $3,664,912.02. The trade was a 8.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Andrew M. Green sold 7,618 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the completion of the sale, the vice president now owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. The trade was a 18.53 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,377 shares of company stock worth $682,356. 8.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Artivion

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AORT. Tidal Investments LLC raised its stake in Artivion by 602.2% during the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock worth $4,179,000 after purchasing an additional 134,642 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after buying an additional 125,668 shares during the period. Perceptive Advisors LLC lifted its holdings in Artivion by 4.7% in the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock valued at $71,658,000 after acquiring an additional 124,725 shares during the last quarter. Sio Capital Management LLC purchased a new position in Artivion in the third quarter worth approximately $3,226,000. Finally, Barclays PLC increased its stake in Artivion by 346.3% during the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock worth $1,888,000 after acquiring an additional 54,996 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.